Blacksmith Medicines Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for FG-2101, a Novel Antibiotic Targeting LpxC
FDA’s designation provides FG-2101 with an additional five years [...]
Blacksmith Medicines Co-Founder Presents at the 21st International Conference on Biological Inorganic Chemistry
Presentation highlights Blacksmith’s novel chemistry platform for targeting metalloenzymes [...]
Blacksmith Medicines Granted U.S. Patent Covering Antibacterial Compounds Targeting LpxC
Patent protection covering clinical candidate FG-2101 composition of matter and [...]
Blacksmith Medicines Announces Presentation at AACR Annual Meeting 2025
SAN DIEGO, April 29, 2025 /PRNewswire/ -- Blacksmith Medicines, [...]
Blacksmith Medicines Presents the Discovery and Chemical Structure of FG-2101, a Novel Antibiotic Candidate Targeting LpxC, at the American Chemical Society (ACS) National Meeting
FG-2101 is Blacksmith’s non-hydroxamate small molecule inhibitor of LpxC [...]
Blacksmith Medicines to Present Preclinical Oncology Data at 8th DDR Inhibitors Summit
SAN DIEGO, California, January 27, 2025 – Blacksmith Medicines, Inc. [...]